M-M-R II market seen topping $1 billion by 2030
The global M-M-R II market is projected to keep growing through 2030 as immunization programs, measles outbreaks and broader preventive-health efforts sustain demand for the measles, mumps and rubella vaccine. Merck & Co. Inc. remains the sole supplier, and North America is expected to stay the biggest regional market.
Why it matters: - The M-M-R II vaccine sits inside routine childhood immunization programs, so demand tracks public-health policy, outbreak response and vaccine access. - The market’s growth matters because measles, mumps and rubella remain preventable diseases that can still pressure health systems when coverage slips. - Merck & Co. Inc. remains the only supplier, making the market highly concentrated.
What happened: - The Business Research Company said the global M-M-R II market is on a steady growth path through 2030. - Merck & Co. Inc. reaffirmed support for the U.S. Child and Adolescent Immunization Schedule in January 2026, reinforcing the vaccine’s role in routine childhood vaccination. - The report says the market is expected to reach more than $1 billion by 2030. - The same forecast puts the M-M-R II market at a 5% compound annual growth rate through 2030. - A free sample of the report is available from The Business Research Company.
The details: - Government vaccination programs and broader immunization campaigns are estimated to add about 2.0% annual growth. - Rising measles and other preventable disease outbreaks are expected to contribute roughly 1.5% annual growth. - Parent, provider and community awareness of preventive healthcare is adding about 1.0% annual growth. - The report says the broader vaccines market is expected to reach about $226 billion by 2030. - The report places the wider pharmaceuticals market at nearly $2.5 trillion by 2030. - M-M-R II would represent close to 0.02% of that broader pharmaceuticals market. - North America is forecast to remain the largest regional market in 2030 at $0.48 billion, up from $0.38 billion in 2025. - The United States is expected to be the largest country market at $0.46 billion in 2030. - The measles segment is projected to hold 51% of the market, or about $0.3 billion in 2030. - The report says measles will add $0.1 billion by 2030, mumps $0.04 billion and rubella $0.02 billion. - The vaccine is offered mainly as a live attenuated formulation and in pre-filled syringes. - Distribution runs through hospitals, pediatric clinics, public health agencies and retail pharmacies. - End users include infants, children and adults. - Merck & Co. Inc. held 100% of sales as of 2025.
Between the lines: - The market outlook depends less on new competitors and more on immunization policy, supply resilience and outbreak pressure. - High regulatory and manufacturing barriers help explain why Merck continues to control the category. - The report’s growth assumptions suggest stable, not explosive, expansion for a mature vaccine market. - The concentration of supply leaves public-health planning tied closely to one manufacturer.
What's next: - Continued measles surveillance and immunization campaigns are likely to support near-term demand. - Merck is expected to keep focusing on formulation improvements, manufacturing scale, cold-chain logistics and digital tracking tools. - North American demand will likely remain the key regional driver through 2030. - The report’s forecast implies the measles segment will stay the largest revenue contributor within M-M-R II.
The bottom line: - M-M-R II is a small but steady vaccine market, and public-health policy, outbreak control and Merck’s sole-supplier position will largely determine how fast it grows.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
The Government Daily Review
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.